Flamingo-01 Phase III GP2 Product Press Releases Email Alerts
Greenwich LifeSciences
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • TECHNOLOGY
    • OUR GP2 CANCER IMMUNOTHERAPY PRODUCT
    • CANCER AND IMMUNOTHERAPY OVERVIEW
  • CLINICAL TRIALS
    • COMPLETED PHASE IIB CLINICAL TRIAL
    • FLAMINGO-01 PHASE III CLINICAL TRIAL
  • INVESTORS & MEDIA
    • OVERVIEW
    • NEWS & EVENTS
    • COMPANY INFO
    • STOCK INFO
    • SEC FILINGS
    • GOVERNANCE
  • CONTACT
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • TECHNOLOGY
    • OUR GP2 CANCER IMMUNOTHERAPY PRODUCT
    • CANCER AND IMMUNOTHERAPY OVERVIEW
  • CLINICAL TRIALS
    • COMPLETED PHASE IIB CLINICAL TRIAL
    • FLAMINGO-01 PHASE III CLINICAL TRIAL
  • INVESTORS & MEDIA
    • OVERVIEW
    • NEWS & EVENTS
    • COMPANY INFO
    • STOCK INFO
    • SEC FILINGS
    • GOVERNANCE
  • CONTACT

Presentations

Nasdaq: GLSI

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Presentations
    • FAQ
  • Stock Info
  • SEC Filings
  • Governance
  • Company Info

  • Presentations
  • FAQ
Corporate Presentation - September 2022 (PDF)
Sep 21, 2022

Corporate Presentation - September 2022 (PDF)

Corporate Presentation - November 2021 (Webcast)
Nov 9, 2021

Corporate Presentation - November 2021 (Webcast)

RSS

By proceeding to use this website, you consent to our use of cookies as described in our Privacy Policy.

Email Alerts

Sign up Now

Sign me up for:

  • Tear Sheet
  • RSS Feed
Logo of Greenwich LifeSciences.

Copyright © 2023

Greenwich LifeSciences, Inc.

ABOUT
TECHNOLOGY
CLINICAL TRIALS
INVESTORS & MEDIA
CONTACT
Privacy Policy
Disclaimer
Sitemap
Logo of Greenwich LifeSciences.

Copyright © 2023

Greenwich LifeSciences, Inc.

ABOUT
TECHNOLOGY
CLINICAL TRIALS
INVESTORS & MEDIA
CONTACT
Disclaimer
Privacy Policy
Sitemap